BR112013002525A2 - vírus da laringotraqueíte infecciosa (iltv) modificado e usos do mesmo - Google Patents

vírus da laringotraqueíte infecciosa (iltv) modificado e usos do mesmo

Info

Publication number
BR112013002525A2
BR112013002525A2 BR112013002525A BR112013002525A BR112013002525A2 BR 112013002525 A2 BR112013002525 A2 BR 112013002525A2 BR 112013002525 A BR112013002525 A BR 112013002525A BR 112013002525 A BR112013002525 A BR 112013002525A BR 112013002525 A2 BR112013002525 A2 BR 112013002525A2
Authority
BR
Brazil
Prior art keywords
iltv
iltvs
attenuated
infectious laryngotracheitis
bird
Prior art date
Application number
BR112013002525A
Other languages
English (en)
Portuguese (pt)
Inventor
Alice Mundt
Egbert Mundt
Maricarmen Garcia
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of BR112013002525A2 publication Critical patent/BR112013002525A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16061—Methods of inactivation or attenuation
    • C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112013002525A 2010-08-02 2011-08-02 vírus da laringotraqueíte infecciosa (iltv) modificado e usos do mesmo BR112013002525A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36998610P 2010-08-02 2010-08-02
PCT/US2011/046263 WO2012018813A2 (en) 2010-08-02 2011-08-02 Modified infectious laryngotracheitis virus (iltv) and uses thereof

Publications (1)

Publication Number Publication Date
BR112013002525A2 true BR112013002525A2 (pt) 2016-05-31

Family

ID=45560025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002525A BR112013002525A2 (pt) 2010-08-02 2011-08-02 vírus da laringotraqueíte infecciosa (iltv) modificado e usos do mesmo

Country Status (8)

Country Link
US (1) US20130129780A1 (enExample)
EP (1) EP2600892A4 (enExample)
JP (1) JP2013535214A (enExample)
BR (1) BR112013002525A2 (enExample)
MX (1) MX2013001349A (enExample)
PH (1) PH12013500156A1 (enExample)
WO (1) WO2012018813A2 (enExample)
ZA (1) ZA201300537B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013178A1 (en) * 2013-07-23 2015-01-29 University Of Maryland Infectious laryngotracheitis virus (iltv) vaccine using recombinant newcastle disease virus vector
US10201604B2 (en) 2013-10-29 2019-02-12 University Of Delaware Live attenuated infectious laryngotracheitis virus (ILTV) vaccines and preparation thereof
US10196616B2 (en) * 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
CN112175048A (zh) * 2020-10-03 2021-01-05 四川省畜牧科学研究院 一种抗原肽、传染性喉气管炎病毒的抗体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723584A4 (en) * 1993-09-24 2000-12-20 Syntro Corp INFECTIOUS LARYNGOTRACHEITIS RECOMBINANT VIRUSES AND USES THEREOF
US5817320A (en) * 1994-06-20 1998-10-06 The United States Of America As Represented By The Secretary Of The Agriculture In ovo immunization of avian embryos with oil-emulsion vaccines
FR2750866B1 (fr) * 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2757061B1 (fr) * 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
JPWO2005093070A1 (ja) * 2004-03-29 2008-02-14 日本ゼオン株式会社 組み換えヘルペスウイルス及びその利用
JP2005287422A (ja) * 2004-03-31 2005-10-20 Nippon Zeon Co Ltd 組み換えヘルペスウイルス及び多価ワクチン
CN101210248A (zh) * 2006-12-30 2008-07-02 河南农业大学 一种ILTV gD糖蛋白核苷酸序列和氨基酸序列及其重组的病毒疫苗以及该疫苗的应用

Also Published As

Publication number Publication date
EP2600892A4 (en) 2014-03-05
PH12013500156A1 (en) 2013-03-18
EP2600892A2 (en) 2013-06-12
MX2013001349A (es) 2013-06-28
US20130129780A1 (en) 2013-05-23
WO2012018813A2 (en) 2012-02-09
ZA201300537B (en) 2014-04-26
JP2013535214A (ja) 2013-09-12
WO2012018813A3 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
MX2016002160A (es) Vacuna para adenovirus aviar.
WO2015024929A3 (en) Fowl adenovirus vaccine
Firouzi et al. Effects of color lights on performance, immune response and hematological indices of broilers
Pasick et al. Avian influenza in north America, 2009–2011
BR112018010503A2 (pt) ovo de ave, método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, ave transgênica, e método para produzir uma ave
BRPI0509104A (pt) métodos e aparelho para injeção por jato automática de ovos de aves
Bertelsen et al. Serological response to vaccination against avian influenza in zoo-birds using an inactivated H5N9 vaccine
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
Kaleta et al. Isolation of herpesvirus and Newcastle disease virus from White Storks (Ciconia ciconia) maintained at four rehabilitation centres in northern Germany during 1983 to 2001 and failure to detect antibodies against avian influenza A viruses of subtypes H5 and H7 in these birds
MX2016016885A (es) Administracion in ovo de cultivos probioticos.
Peeters et al. Pulmonary immunization of chickens using non-adjuvanted spray-freeze dried whole inactivated virus vaccine completely protects against highly pathogenic H5N1 avian influenza virus
Chrząstek et al. Class B CpG ODN stimulation upregulates expression of TLR21 and IFN-γ in chicken Harderian gland cells
Bublot et al. Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand
PH12013500156A1 (en) Modified infectious laryngotracheitis virus (iltv) and uses thereof
Delogu et al. Serologic and virologic evidence of influenza a viruses in wild boars (Sus scrofa) from two different locations in Italy
RU2019137459A (ru) Вакцины на основе реовирусов птиц
RU2010113459A (ru) Вакцина ассоциированная против ньюкаслской болезни птиц, инфекционного бронхита кур, синдрома снижения яйценоскости-76, инфекционной бурсальной болезни и реовирусного теносиновита птиц инактивированная эмульсионная
Ezeibe et al. In vitro and in vivo effects of aluminium magnesium silicate on infectious bursal disease virus in chicken.
Wakawa et al. Surveillance for Avian Influenza H_ (5) Antibodies and Viruses in Commercial Chicken Farms in Kano State, Nigeria
HK1184691A (en) Modified infectious laryngotracheitis virus (iltv) and uses thereof
Oana et al. Serological screening for avian reovirosis.
Alizadeh et al. In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine
Mustafa et al. Newcastle disease as an emerging disease in peacocks of Tharparker, Pakistan
Ma et al. Intranasal Mosaic H1N1 Live Attenuated Influenza Vaccine Elicits Broad Cross‐Reactive Immunity and Protection Against Group 1 and 2 Influenza A Viruses
Hashemzade et al. Effect of infectious bursal disease virus on response of turkeys to infection by avian influenza virus (H9N2).

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.